{"title":"【Venetoclax联合阿扎胞苷治疗新诊断急性髓系白血病与“3+7”及类似方案比较的回顾性分析】。","authors":"Lu-Lu Wang, Juan Zhang, Yue Zhang, Yong Zhang, Xiao-Min Dong, Dan-Yang Zhang, Ting-Ting Chen, Yun-Hui Zhou, Teng Wang, Hui-Ling Lan, He-Bing Zhou","doi":"10.19746/j.cnki.issn.1009-2137.2025.03.008","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To retrospectively analyze the clinical data of newly diagnosed acute myeloid leukemia (AML) patients treated with venetoclax combined with azacitidine (Ven/Aza) or standard \"3+7\" regimen and similar regimens, collect real-world study data, compare the treatment response and adverse events between the two regimens, as well as perform survival analysis.</p><p><strong>Methods: </strong>To retrospectively analyze the efficacy, survival, and adverse reactions of newly diagnosed AML patients treated with Ven/Aza (24 cases) and \"3+7\" regimens (117 cases ) in our hospital from September 2009 to March 2023, as well as factors influencing outcomes. A propensity score matching (PSM) was performed on age and Eastern Cooperative Oncology Group performance status (ECOG PS) to obtain a 1:1 matched cohort of 20 pairs, and the efficacy and survival before and after the matching were compared.</p><p><strong>Results: </strong>The median age of patients in the Ven/Aza group was 69 years, while that in the \"3+7\" group was 56 years (<i>P</i> <0.001). Objective remission rate (ORR) was 62.5% in Ven/Aza group and 74.8% in \"3+7\" group (<i>P</i> >0.05). The median overall survival (OS) in the Ven/Aza group was 522 days, while that in the \"3+7\" group was 1 002 days (<i>P</i> >0.05). After controlling the two variables of age and ECOG PS, a PSM cohort of 20 pairs was obtained, in which the ORR was 65% in Ven/Aza group and 60% in \"3+7\" group (<i>P</i> >0.05). The median OS was 522 days and 629 days, and median progression-free survival (PFS) was 531 days and 198 days between the two groups, respectively. There were no statistically significant differences in OS and PFS between the two groups (both <i>P</i> >0.05). Additionally, the incidence of adverse events in the Ven/Aza group was significantly reduced.</p><p><strong>Conclusion: </strong>The overall cohort shows that the \"3+7\" regimen has advantages in efficacy and survival, but Ven/Aza regimen is relatively safer. After performing PSM on age and ECOG PS, the Ven/Aza group showed improved efficacy, and a longer median PFS compared to \"3+7\" group.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 3","pages":"672-681"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Retrospective Analysis of Venetoclax Combined with Azacitidine Compared with \\\"3+7\\\" or Similar Regimens for Newly Diagnosed Patients with Acute Myeloid Leukemia].\",\"authors\":\"Lu-Lu Wang, Juan Zhang, Yue Zhang, Yong Zhang, Xiao-Min Dong, Dan-Yang Zhang, Ting-Ting Chen, Yun-Hui Zhou, Teng Wang, Hui-Ling Lan, He-Bing Zhou\",\"doi\":\"10.19746/j.cnki.issn.1009-2137.2025.03.008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To retrospectively analyze the clinical data of newly diagnosed acute myeloid leukemia (AML) patients treated with venetoclax combined with azacitidine (Ven/Aza) or standard \\\"3+7\\\" regimen and similar regimens, collect real-world study data, compare the treatment response and adverse events between the two regimens, as well as perform survival analysis.</p><p><strong>Methods: </strong>To retrospectively analyze the efficacy, survival, and adverse reactions of newly diagnosed AML patients treated with Ven/Aza (24 cases) and \\\"3+7\\\" regimens (117 cases ) in our hospital from September 2009 to March 2023, as well as factors influencing outcomes. A propensity score matching (PSM) was performed on age and Eastern Cooperative Oncology Group performance status (ECOG PS) to obtain a 1:1 matched cohort of 20 pairs, and the efficacy and survival before and after the matching were compared.</p><p><strong>Results: </strong>The median age of patients in the Ven/Aza group was 69 years, while that in the \\\"3+7\\\" group was 56 years (<i>P</i> <0.001). Objective remission rate (ORR) was 62.5% in Ven/Aza group and 74.8% in \\\"3+7\\\" group (<i>P</i> >0.05). The median overall survival (OS) in the Ven/Aza group was 522 days, while that in the \\\"3+7\\\" group was 1 002 days (<i>P</i> >0.05). After controlling the two variables of age and ECOG PS, a PSM cohort of 20 pairs was obtained, in which the ORR was 65% in Ven/Aza group and 60% in \\\"3+7\\\" group (<i>P</i> >0.05). The median OS was 522 days and 629 days, and median progression-free survival (PFS) was 531 days and 198 days between the two groups, respectively. There were no statistically significant differences in OS and PFS between the two groups (both <i>P</i> >0.05). Additionally, the incidence of adverse events in the Ven/Aza group was significantly reduced.</p><p><strong>Conclusion: </strong>The overall cohort shows that the \\\"3+7\\\" regimen has advantages in efficacy and survival, but Ven/Aza regimen is relatively safer. After performing PSM on age and ECOG PS, the Ven/Aza group showed improved efficacy, and a longer median PFS compared to \\\"3+7\\\" group.</p>\",\"PeriodicalId\":35777,\"journal\":{\"name\":\"中国实验血液学杂志\",\"volume\":\"33 3\",\"pages\":\"672-681\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中国实验血液学杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.03.008\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国实验血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.03.008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
[Retrospective Analysis of Venetoclax Combined with Azacitidine Compared with "3+7" or Similar Regimens for Newly Diagnosed Patients with Acute Myeloid Leukemia].
Objective: To retrospectively analyze the clinical data of newly diagnosed acute myeloid leukemia (AML) patients treated with venetoclax combined with azacitidine (Ven/Aza) or standard "3+7" regimen and similar regimens, collect real-world study data, compare the treatment response and adverse events between the two regimens, as well as perform survival analysis.
Methods: To retrospectively analyze the efficacy, survival, and adverse reactions of newly diagnosed AML patients treated with Ven/Aza (24 cases) and "3+7" regimens (117 cases ) in our hospital from September 2009 to March 2023, as well as factors influencing outcomes. A propensity score matching (PSM) was performed on age and Eastern Cooperative Oncology Group performance status (ECOG PS) to obtain a 1:1 matched cohort of 20 pairs, and the efficacy and survival before and after the matching were compared.
Results: The median age of patients in the Ven/Aza group was 69 years, while that in the "3+7" group was 56 years (P <0.001). Objective remission rate (ORR) was 62.5% in Ven/Aza group and 74.8% in "3+7" group (P >0.05). The median overall survival (OS) in the Ven/Aza group was 522 days, while that in the "3+7" group was 1 002 days (P >0.05). After controlling the two variables of age and ECOG PS, a PSM cohort of 20 pairs was obtained, in which the ORR was 65% in Ven/Aza group and 60% in "3+7" group (P >0.05). The median OS was 522 days and 629 days, and median progression-free survival (PFS) was 531 days and 198 days between the two groups, respectively. There were no statistically significant differences in OS and PFS between the two groups (both P >0.05). Additionally, the incidence of adverse events in the Ven/Aza group was significantly reduced.
Conclusion: The overall cohort shows that the "3+7" regimen has advantages in efficacy and survival, but Ven/Aza regimen is relatively safer. After performing PSM on age and ECOG PS, the Ven/Aza group showed improved efficacy, and a longer median PFS compared to "3+7" group.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
